Opinion on Pharmaceutical Manufacturers in Japan

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | » »|

Type Product title / description Pub Price
Expert View
Expert View

Japanese pharmaceutical companies: Survival through improved R&D

The Japanese market is the second largest pharmaceutical market globally, after the US. The market is therefore an attractive target for western companies' expansion plans. The building of strong in-house R&D capabilities will be central to Japanese Pharma companies' strategies for survival. However, improving R&D capabilities will not be achieved by increasing spending alone.

Published By Datamonitor
02 Feb 2004
Expert View
Expert View

Mycamine - bolstering the antifungal armory

Fujisawa's Mycamine is the second product in the novel class of the echinocandins to be approved for use in the US. Mycamine has witnessed rapid uptake in its first market, Japan, generating $106 million of sales in 2004. Indeed, the staggered geographic launch of the drug, made necessary by delays in gaining approval in the US and EU, may actually contribute to its future commercial success.

Published By Datamonitor
23 Mar 2005
Expert View
Expert View

Western invasion threatens Japanese pharma's survival

After the US, the Japanese market is the second largest pharmaceutical market in the world, with estimated sales of $54 billion in 2003. While the size of the Japanese market makes it an attractive target for western companies' expansion plans, domestic players are finding it increasingly difficult to survive.

Published By Datamonitor
12 Apr 2005
Expert View
Expert View

Novel combinations breathe new life into COPD market

There are 31.2 million COPD sufferers in the US, Europe and Japan - a prevalence rate of approximately 4.4% of the general population. Thus, the development of novel dual-action, once-daily inhaled therapies will provide important new treatment options for COPD and play a major role in the expansion of the market over the next decade.

Published By Datamonitor
13 May 2005
ResearchWire
ResearchWire

Cancer therapies: cytotoxics rise and fall

Published By Datamonitor
23 Sep 2005
CommentWire
CommentWire

Takeda: an East wind blows good for Blopress

Japanese regulators have approved Takeda's Blopress in chronic heart failure (CHF), proving Takeda's lifecycle management strategy for the drug successful. Furthermore, the approval makes Blopress the first angiotensin receptor blocker (ARB) to be approved in CHF in all of the major pharmaceutical markets - Japan, the US and Europe - giving it a significant strategic advantage in this indication.

Published By Datamonitor
13 Oct 2005
CommentWire
CommentWire

Daiichi Sankyo: ACAT inhibitor is back in the bag

Daiichi Sankyo has halted clinical development of its heart drug candidate CS-505 following its poor performance in an atherosclerosis study. This will be a significant blow to the company as many industry spectators had predicted blockbuster status for the drug. However, the news will please Pfizer and Roche, which are both developing novel atherosclerosis treatments themselves.

Published By Datamonitor
26 Oct 2005
CommentWire
CommentWire

Daiichi Sankyo: pipeline filling at the O-KAI Corral

Daiichi Sankyo has signed a deal worth up to $340 million with KAI Pharmaceuticals for the global development and commercialization of KAI-9803, an experimental treatment for the prevention of myocardial tissue death. While this could represent an astute move by Daiichi to boost its cardio business, it could also be seen as a desperate pipeline-filling attempt following CS-505's recent failure.

Published By Datamonitor
11 Jan 2006
CommentWire
CommentWire

Takeda: hypertension hurdles

Takeda has moved TAK-491 into phase II, thus accelerating the development of a follow-on product to its blockbuster hypertension drug Blopress, which now has two potential successors in phase II development. However, given the dynamics of the hypertension market and the fact that either Blopress successor would be a late entrant to the market, Takeda's investors must be worried.

Published By Datamonitor
12 Jul 2006
CommentWire
CommentWire

Takeda Pharmaceutical: joint venture with Abbott to split

Takeda Pharmaceutical and Abbott Laboratories have announced the imminent conclusion of their joint venture, TAP Pharmaceutical Products. The value of TAP has become questionable in recent years, and the decision to end the partnership is expected to be a positive strategy for both parties. TAP's flagship drugs are to be divided between both companies.

Published By Datamonitor
20 Mar 2008

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | » »|

No help is available.